In addition to the SP263 clone, in a separate mini-method comparison study, we also compared the PD-L1 CAL10 assay to other comparative assays, including 22C3 (pharmDx-Agilent Dako, Agilent Technologies, Inc., Santa Clara, USA) and 28-8 (pharmDx-Agilent Dako, Agilent Technologies, Inc., Santa Clara, USA), on each assay’s manufacturer-recommended staining platforms using NSCLC samples. The gene discussed is CD274; the disease is non-small cell lung carcinoma.